Rheumatologists said more data are needed to determine optimal glucocorticoid tapering and treatment duration of avacopan for patients with ANCA-associated vasculitis.
A unique study in patients with renal cell carcinoma on tyrosine kinase inhibitors (TKIs) shows that taking a break from the drugs is feasible and cost-effective.
The study findings add new insights, but also raise new questions, about the best treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia.